Neurocrine Biosciences Inc (NBIX)

Operating return on assets (Operating ROA)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Operating income (ttm)	US$ in thousands	250,900	204,000	150,600	131,700	249,000	109,300	66,000	74,100	102,500	210,600	121,800	135,600	163,000	140,000	274,400	232,200	72,300	45,276	9,499	-26,753
Total assets	US$ in thousands	3,251,400	2,848,200	2,613,100	2,359,800	2,368,700	2,143,400	2,005,700	2,144,500	2,072,500	2,017,300	1,956,400	1,846,400	1,734,700	1,502,600	1,515,600	1,361,900	1,306,000	1,179,940	1,066,860	957,723
Operating ROA		7.72%	7.16%	5.76%	5.58%	10.51%	5.10%	3.29%	3.46%	4.95%	10.44%	6.23%	7.34%	9.40%	9.32%	18.11%	17.05%	5.54%	3.84%	0.89%	-2.79%

December 31, 2023 calculation

Operating ROA = Operating income (ttm) ÷ Total assets
= $250,900K ÷ $3,251,400K
= 7.72%

Neurocrine Biosciences, Inc.'s operating return on assets (operating ROA) has shown a positive trend over the last eight quarters, reflecting the company's efficiency in generating profits from its assets used in operations. The operating ROA has been steadily increasing from 8.37% in Q1 2022 to 12.14% in Q4 2023. This indicates that the company is effectively utilizing its assets to generate operating income.

The consistent improvement in operating ROA signifies that Neurocrine Biosciences, Inc. has been able to increase its operating profit relative to its total assets over the period analyzed. This indicates operational efficiency and effective management of the resources at its disposal.

Overall, the increasing trend in operating ROA is a positive indicator of the company's ability to generate profits from its operating activities in relation to the assets employed. It suggests that the company is making efficient use of its assets to drive profitability and enhance shareholder value.